EVAX
Price
$5.18
Change
-$0.16 (-3.00%)
Updated
Nov 21 closing price
Capitalization
43.01M
Intraday BUY SELL Signals
SPRB
Price
$105.00
Change
+$2.39 (+2.33%)
Updated
Nov 21 closing price
Capitalization
112.39M
Intraday BUY SELL Signals
Interact to see
Advertisement

EVAX vs SPRB

Header iconEVAX vs SPRB Comparison
Open Charts EVAX vs SPRBBanner chart's image
Evaxion A/S
Price$5.18
Change-$0.16 (-3.00%)
Volume$115.45K
Capitalization43.01M
Spruce Biosciences
Price$105.00
Change+$2.39 (+2.33%)
Volume$305.25K
Capitalization112.39M
EVAX vs SPRB Comparison Chart in %
EVAX
Daily Signal:
Gain/Loss:
SPRB
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
EVAX vs. SPRB commentary
Nov 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVAX is a Hold and SPRB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 23, 2025
Stock price -- (EVAX: $5.18 vs. SPRB: $105.00)
Brand notoriety: EVAX and SPRB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EVAX: 5% vs. SPRB: 43%
Market capitalization -- EVAX: $43.01M vs. SPRB: $112.39M
EVAX [@Biotechnology] is valued at $43.01M. SPRB’s [@Biotechnology] market capitalization is $112.39M. The market cap for tickers in the [@Biotechnology] industry ranges from $108.28B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EVAX’s FA Score shows that 0 FA rating(s) are green whileSPRB’s FA Score has 0 green FA rating(s).

  • EVAX’s FA Score: 0 green, 5 red.
  • SPRB’s FA Score: 0 green, 5 red.
According to our system of comparison, EVAX is a better buy in the long-term than SPRB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EVAX’s TA Score shows that 2 TA indicator(s) are bullish while SPRB’s TA Score has 2 bullish TA indicator(s).

  • EVAX’s TA Score: 2 bullish, 6 bearish.
  • SPRB’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, SPRB is a better buy in the short-term than EVAX.

Price Growth

EVAX (@Biotechnology) experienced а -5.13% price change this week, while SPRB (@Biotechnology) price change was -1.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.01%. For the same industry, the average monthly price growth was -3.31%, and the average quarterly price growth was +62.87%.

Industries' Descriptions

@Biotechnology (-1.01% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SPRB($112M) has a higher market cap than EVAX($43M). SPRB YTD gains are higher at: 233.333 vs. EVAX (22.546). EVAX has higher annual earnings (EBITDA): -11.76M vs. SPRB (-48.11M). EVAX has higher revenues than SPRB: EVAX (3.18M) vs SPRB (1.3M).
EVAXSPRBEVAX / SPRB
Capitalization43M112M38%
EBITDA-11.76M-48.11M24%
Gain YTD22.546233.33310%
P/E RatioN/AN/A-
Revenue3.18M1.3M244%
Total Cash14.7MN/A-
Total Debt11.3MN/A-
TECHNICAL ANALYSIS
Technical Analysis
EVAXSPRB
RSI
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 16 days ago
84%
Bullish Trend 5 days ago
77%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
EVAX
Daily Signal:
Gain/Loss:
SPRB
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PYXS4.800.27
+5.96%
Pyxis Oncology
ATNM1.330.04
+3.10%
Actinium Pharmaceuticals
ODFJF8.010.06
+0.75%
ODFJELL DRILLING LTD.
FTGFF7.220.01
+0.15%
Firan Technology Group Corporation
BKKLY25.20-0.28
-1.10%
Bangkok Bank Public Co Ltd.

EVAX and

Correlation & Price change

A.I.dvisor tells us that EVAX and KURA have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EVAX and KURA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVAX
1D Price
Change %
EVAX100%
-3.00%
KURA - EVAX
31%
Poorly correlated
+1.73%
KYTX - EVAX
28%
Poorly correlated
-4.70%
HYPD - EVAX
28%
Poorly correlated
-7.18%
SPRB - EVAX
27%
Poorly correlated
+2.33%
REPL - EVAX
26%
Poorly correlated
+2.11%
More

SPRB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRB has been loosely correlated with NEVPF. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRB jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRB
1D Price
Change %
SPRB100%
+2.33%
NEVPF - SPRB
61%
Loosely correlated
N/A
IMRX - SPRB
52%
Loosely correlated
+4.43%
MLEC - SPRB
51%
Loosely correlated
-4.38%
IMCR - SPRB
37%
Loosely correlated
+0.87%
VYNE - SPRB
35%
Loosely correlated
+1.03%
More